FEMY Stock Overview
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Femasys Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.31 |
| 52 Week High | US$4.75 |
| 52 Week Low | US$0.25 |
| Beta | -2.99 |
| 1 Month Change | -34.50% |
| 3 Month Change | 63.75% |
| 1 Year Change | 52.31% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.08% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?
Apr 03
Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation
Sep 27Femasys commercially launches Femcerv for cervical cancer screening
Sep 29Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M
Aug 10We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully
May 22Femasys: Revolutionizing Female Reproduction
Jul 16Shareholder Returns
| FEMY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.4% | -4.4% | -3.7% |
| 1Y | 52.3% | -2.8% | 20.2% |
Return vs Industry: FEMY exceeded the US Medical Equipment industry which returned -2.2% over the past year.
Return vs Market: FEMY exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| FEMY volatility | |
|---|---|
| FEMY Average Weekly Movement | 17.9% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FEMY's share price has been volatile over the past 3 months.
Volatility Over Time: FEMY's weekly volatility has decreased from 57% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 33 | Kathy Lee-Sepsick | www.femasys.com |
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
Femasys Inc. Fundamentals Summary
| FEMY fundamental statistics | |
|---|---|
| Market cap | US$28.95m |
| Earnings (TTM) | -US$14.25m |
| Revenue (TTM) | US$1.07m |
27.0x
P/S Ratio-2.0x
P/E RatioIs FEMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FEMY income statement (TTM) | |
|---|---|
| Revenue | US$1.07m |
| Cost of Revenue | US$380.07k |
| Gross Profit | US$691.90k |
| Other Expenses | US$14.94m |
| Earnings | -US$14.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 64.54% |
| Net Profit Margin | -1,329.06% |
| Debt/Equity Ratio | 23.2% |
How did FEMY perform over the long term?
See historical performance and comparison